On Jan 27th Progressive Care (OTCMKTS: RXMD) released a PR announcing their alliance with health Care of South Florida with the intentions to launch Medication Monitoring and Health Safety Programs. The demand for health care is rising. Everyday estimates show that 11,000 people turn 65 years old and almost 70% of negative health events occurring after a hospital discharge are related to medication management.
Our call to premium members saw this stock hit highs of $0.08 from $0.002-$0.003 in a matter of weeks! Watching for Another Rally to Spark and RXMD may be something to watch today! Click Here to Subscribe to Penny Stock Hub NOW and don’t miss our next monster.
Jan 27th the stock opened at $0.04 and by Jan 30th RXMD saw a high of $0.08 that’s a 100% increase in 3 days. Since then the stock has gradually declined to its current price of $0.021. The last time RXMD saw these price levels it jumped to it’s high of $0.08. This is a penny stock that has a lot of eyes on it for 2015. A short term plays with the potential to make a quick profit. Furthermore, we continue to watch this for yet another massive run.
About Progressive Care Inc:
Progressive Care Inc. (OTCMKTS: RXMD) (“Progressive” or the “Company”), a South Florida provider of prescription pharmaceuticals specializing in health practice risk management, the sale of anti-retroviral medications and related medication therapy management, the sale and rental of durable medical equipment (“DME”) and the supply of prescription medications to long term care facilities, announces new medication monitoring and health safety program with Health Care of South Florida.
Small Caps Under The Microscope
Small cap stocks are the leading catalyst for the novice investor. Commonly known to investors as “Penny Stocks”; Penny stocks are traded on over-the-counter markets (OTC) through the use of electronic quotation systems called “pink sheets.” Penny stocks are higher risk inexpensive stocks that trade for less than $5. Some investors feel that penny stocks have the biggest opportunity for gains.
Now what attracts investors/perspective investors is the cost of the stock, the ability to “buy low, sell high”. Timing is very crucial when choosing the right small cap stock, ideally to capitalize on the most profitable gains, an investor would want to buy at the lowest price possible. Penny stocks are high risk/High reward when compared to “blue chip” stocks, which are more stable, but if one trades the right way the potential to make some fat profit is there.
Progressive Green Solutions (OTCMKTS: PGSC) is known as a penny stock that is in the discussion of many small cap investors. This small cap stock has seen prices runs from lows of $0.36 to highs of $1.44. Currently the price and stock support levels, today’s prices may offer an opportunity for small cap investors to take capitalize a situation where a stock may be considered “under the radar”. For more information on PGSC the link below provides an in-depth small cap stock analysis on the company: http://bit.ly/PGSC_Report
Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)
Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.
Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.
Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).
That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).
The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.
Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.
The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.
Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.
Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)
Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.
Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.
Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.
Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.
The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.
Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.
Bristol-Myers declined to comment.
Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.
The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.
Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.
On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.
Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.
The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.